1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Nexsen Limited

Nexsen Limited

NXN.AX
Nexsen LimitedAU flagAustralian Securities Exchange
0.13
AUD
+0.02
- -
26.26MMarket Cap
2025 Y
2026 Y
Revenue per Share
- -
- -
Basic EPS, GAAP
- -
-0.04
Free Cash Flow per Basic Share
- -
- -
Dividend per Share
- -
- -
Book Value per Share
- -
0.03
Tangible Book Value per Share
- -
0.02
Basic Weighted Avg Shares
200
180
Sales/Revenue/Turnover
- -
- -
Operating Margin (%)
- -
- -
Depreciation Expense
- -
- -
Net Income, GAAP
- -
-7
Effective Tax Rate (%)
- -
- -
Profit Margin (%)
- -
- -
Working Capital
- -
4
LT Debt
- -
- -
Total Equity
- -
6
Return on Invested Capital (%)
- -
- -
Return on Capital (%)
- -
- -
Return on Common Equity (%)
- -
-231.53

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
-0.04

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Mark Anthony Muzzin
Sector
Healthcare
Industry
Biotechnology
Address
4 Bridge Street Sydney NSW Australia 2000
IPO Date
Oct 13, 2025
Website
nexsen.bio
Similar Companies
Bicycle Therapeutics plc (BCYC)
ReNeuron Group plc (RNUGF)
Pharma Equity Group A/S (PEG.CO)
Caladrius Biosciences, Inc. (CLBS)
Myovant Sciences Ltd. (MYOV)
Aeterna Zentaris Inc. (AEZS.TO)
Business
Nexsen Limited operates as a nanobiotechnology company that develops proprietary biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for veterinary, agricultural, and biosecurity applications. The company offers Group B Streptococcus (GBS) rapid sensor, a diagnostic for the detection of human GBS in expectant mothers; kidney diseases, a POC tests for the screening, detection, and ongoing monitoring of various subsets of acute kidney injury and chronic kidney disease; bovine mastitis, a farm diagnostic to detect mastitis early which helps farmers; biosecurity pathogen tests, a portable sensor for frontline detection of invasive pests and pathogens -built for customs officers, farmers, and quarantine zones. The company was incorporated in 2021 and is based in Sydney, Australia.